Staff Financial Analyst
Bylines
WMT trades at roughly 38x forward earnings, well above Target and its own 10-year average, while the stock has gone nowhere in 2026. The bull and bear case, explained.
NKE trades at 18.7x trailing earnings vs. a 33x 10-year median, but forward P/E is higher, not lower. Here's what that gap says about whether the discount is real.
META trades near 30% below its August 2025 peak on a forward P/E below its trailing multiple — a real bargain signal, unless a child-safety trial seeking $200 billion in damages changes the math.
BABA's forward P/E ran from roughly 11x in early 2024 to a ~34x AI-euphoria peak in October 2025, cratered after Anthropic accused Alibaba's Qwen lab of 'harvesting' Claude, and has rebuilt to 18.96x heading into the Aug. 20 earnings call. Here's what moved the multiple in each phase.
INTU's trailing P/E ran from 66-73x in 2024 to an all-time high near $806, then fell under 16x by mid-2026 as Wall Street repriced TurboTax for AI disruption
HD's trailing P/E bottomed near 16.5x in the 2022 rate shock and has since round-tripped through a 2024 M&A-driven re-rating to sit near 25x today, even as trailing earnings shrink. Here's what actually moved the multiple in each phase.
ADI's trailing P/E tripled from 29x to as high as 78x between January 2024 and mid-2026, but the PEG ratio that's supposed to justify a multiple like that stopped computing in December 2024 and still hasn't come back. Here's what actually happened in each phase.
CPI cooled to 3.4%, PPI held flat, and payrolls missed big — yet the S&P 500 keeps hitting records. How inflation data is shaping Fed policy and stocks in 2026.
JNJ traded at under 11x trailing earnings in 2024 and near 30x in 2026. The company didn't change nearly as much as the multiple did — here's what actually happened to Johnson & Johnson's stock, and what it says about pricing it today.